Granite (NYSE:GVA) announced today that it has begun work for a $13 million task order at the Homewood, Illinois Station as part of a Multiple Award Construction Contract (MACC) for Americans with Disabilities Act (ADA) Stations Program by The National Railroad Passenger Corporation (Amtrak). The project contract will be included in Granite’s third quarter 2020 backlog.
Granite was one of eight contractors selected in 2019 to participate in Amtrak’s ADA Stations Program MACC. The $100 million indefinite delivery/indefinite quantity (IDIQ) competitive MACC is comprised of task orders ranging from $25 thousand to $25 million, for five base years ending in 2023, plus five, one-year options through 2028. Granite is currently completing four ADA compliance upgrade projects that were previously awarded by Amtrak under this MACC Program, two in Montana and two in New York.
Amtrak’s ADA Stations Program is a comprehensive program to make the Amtrak-served stations for which Amtrak has ADA responsibility, ADA compliant and accessible. In this task order, Granite will be responsible for the renovation of a portion of the existing Homewood station's building and surrounding site. Scope of work will include modifications to the sidewalks and parking lot, restrooms, existing waiting room seating and wall mounted accessories; and replacement of station entry doors, and ramps at both station entrances and landings. Additional renovations include interior and exterior signage, and the replacement of the existing track level asphalt platform with a new 650-foot boarding platform; the construction of a weather protected ramp from the station level to the existing tunnel; and modernization of platform elevator.
"Given that this project includes multiple stakeholders and a fast-paced schedule, Granite's team has provided and will maintain a detailed phasing plan to ensure this project is safe, high-quality and is completed on-time,” said Granite Regional Vice President Benj Harding. "The robust phasing plan has been developed to minimize disruption to the traveling public.”
Construction is underway and expected to conclude in December 2021.
Granite is America’s Infrastructure Company™. Incorporated since 1922, Granite (NYSE:GVA) is one of the largest diversified construction and construction materials companies in the United States as well as a full-suite provider in the transportation, water infrastructure and mineral exploration markets. Granite’s Code of Conduct and strong Core Values guide the Company and its employees to uphold the highest ethical standards. In addition to being one of the World’s Most Ethical Companies for eleven consecutive years, Granite is an industry leader in safety and an award-winning firm in quality and sustainability. For more information, visit the Granite website, and connect with Granite on LinkedIn, Twitter, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200824005112/en/
PISCATAWAY, N.J., July 24, 2020 /PRNewswire/ -- GenScript, the world's leading gene synthesis provider, today announced that it will highlight recent innovations using designed mutant libraries to advance neurodegenerative disease treatment at the Protein Engineering Congress USA 2020. During a headline keynote by Dr. Meredith Jackrel of Washington University and a GenScript-hosted panel, experts will review how a first-in-class semiconductor-based DNA synthesis platform is advancing protein engineering. They will also discuss GenScript's precision DNA mutant libraries for improving protein properties such as functional activities and binding affinities for biosynthetic, therapeutic, and diagnostic applications.
"Our novel semiconductor-based DNA synthesis platform allows mutant library construction with precise control over codon usage, thereby enabling the minimization of codon bias and uneven distribution of amino acids as well as preventing the introduction of unwanted or stop codons," said Maung Nyan Win, PhD, Sr. Field Applications Scientist, GenScript. "This customizable codon usage will inherently improve the library quality significantly, saving researchers valuable time and effort during the screening and characterization process, and thus ultimately reducing costs and time to market."
During the Congress:
On July 28 at 12 p.m. EDT, Meredith Jackrel, PhD, assistant professor in the Department of Chemistry at Washington University in St. Louis, presents the headline keynote on behalf of GenScript titled, "Engineering protein disaggregases to counter the protein misfolding that underpins neurodegeneration." Dr. Jackrel discusses utilizing protein disaggregases to counter the misfolding that underpins neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. By screening large libraries of Hsp104 variants generated from GenScript's semiconductor-based DNA synthesis platform that comprehensively cover sequence space, Dr. Jackrel aims to uncover variants with improved properties and learn more about the mechanisms of Hsp104 potentiation. Hsp104 is a protein disaggregase from yeast that Dr. Jackrel and team have engineered to counter the misfolding of proteins that aggregate in ALS and Parkinson's disease.
On July 27 at 2:30 p.m. EDT, GenScript hosts the panel "Tailor-Made Mutant Libraries for Precision Engineering," featuring Maung Nyan Win, PhD, Sr. Field Applications Scientist, GenScript; Nicky Caiazza, Co-founder and CSO of Cellibre; and Iman Farasat, Associate Director, Biologics Discovery, The Janssen Pharmaceutical Companies of Johnson & Johnson. The panel will discuss the methods, benefits, and uses of an advanced, arrayed semiconductor-based DNA synthesis platform for construction of high-quality mutant libraries that are devoid of unwanted mutants. The panel will also more broadly discuss the utility of these mutant libraries for biosynthetic and therapeutic applications.
"With the Protein Engineering Congress being the place for showcasing the latest innovations for industrial biocatalysis and synthetic biology-based product development, we are incredibly excited to have market leader GenScript as our headline partner, with Dr. Meredith Jackrel delivering the Day 2 keynote," said Mark Gavhure, Director of Commercial Partnerships for Kisaco Research, sponsor of the event.
The Protein Engineering Congress 2020 gathers scientific and industry leaders to discuss innovations and new techniques in protein and enzyme engineering in industrial applications from pharmaceuticals to specialty chemicals to food and beverages and other consumer goods. Dr. Frances Arnold, recipient of the 2018 Nobel Prize for Chemistry and Linus Pauling Professor, Chemical Engineering, Bioengineering & Biochemistry, will keynote the event.
GenScript is a leading contract research organization providing gene, peptide, protein, CRISPR, and antibody reagents to scientists in over 100 countries worldwide. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents in order to Make Research Easy for all scientists. For more information, visit www.genscript.com.
Contact:CorporateEric Wang, vice president of marketingGenScript(732) 885-9188 ext. email@example.comMediaSusan ThomasPrincipal, Endpoint Communications(619) firstname.lastname@example.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/genscript-highlights-tailor-made-mutant-libraries-for-therapeutic-applications-at-protein-engineering-congress-301099634.html
SOURCE Genscript Biotech Corporation
All amounts expressed in US dollars TORONTO, May 01, 2021 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) confirmed today that it had referred a tax claim by the Senegalese Revenue Authority (SRA) to the International Chamber of Commerce (ICC) for arbitration after numerous attempts to resolve the issue with the government had failed.The SRA has levied an unaudited assessment totaling $208 million (calculated as of March 31, 2021) for taxes it claims arose from Barrick’s sale of its interest in the Massawa project to Teranga Gold Corporation last year. Barrick said the proposed assessment was not in accordance with its investment agreement and relevant legislation in place, and in order to resolve the dispute, Barrick has referred the matter to the ICC which is the dispute resolution forum provided for in its agreement with the State of Senegal.The arbitration process will start when the SRA has appointed its arbitrator. Barrick said in the meantime it would continue to engage with the government to resolve this matter. Barrick and its predecessor Randgold has been a partner and investor in the Senegalese mining industry since 1995, and continues to invest in its exploration projects, as well as through its investment in Endeavour Mining Corp.Enquiries
President and CEOMark Bristow+1 647 205 7694+44 788 071 1386Country Manager SenegalDavid Mbaye+221 76 33 93 714Investor and Media RelationsKathy du Plessis+44 20 7557 7738Email: email@example.comWebsite: www.barrick.com Cautionary Statement on Forward-Looking InformationCertain information contained in this press release, including any information as to Barrick’s strategy, plans, or future financial or operating performance, constitutes “forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements. The words “will”, “would”, “continue” and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to Barrick’s strategy for the resolution of the Senegalese tax dispute through arbitration and continued engagement with the Senegalese Revenue Authority, and Barrick’s continuing investment in exploration projects in Senegal.Forward-looking statements are necessarily based upon a number of estimates and assumptions; including material estimates and assumptions related to the factors set forth below that, while considered reasonable by Barrick as at the date of this press release in light of management’s experience and perception of current conditions and expected developments, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements, and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: timing of receipt of, or failure to comply with, necessary permits and approvals, including with respect to the assumption of closure obligations; the speculative nature of mineral exploration and development; changes in national and local government legislation, taxation, controls, or regulations and/or changes in the administration of laws, policies, and practices, expropriation or nationalization of property and political or economic developments in Senegal; lack of certainty with respect to foreign legal systems, corruption and other factors that are inconsistent with the rule of law; failure to comply with environmental and health and safety laws and regulations; litigation, arbitration and legal and administrative proceedings; risk of loss due to acts of war, terrorism, sabotage and civil disturbances; and damage to Barrick’s reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Barrick’s handling of environmental matters or dealings with community groups, whether true or not. In addition, there are risks and hazards associated with the business of mineral exploration, development, and mining, including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins, flooding, and gold bullion, copper cathode, or gold or copper concentrate losses (and the risk of inadequate insurance, or inability to obtain insurance, to cover these risks).Many of these uncertainties and contingencies can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Readers are cautioned that forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements.Specific reference is made to the most recent Form 40-F/Annual Information Form on file with the SEC and Canadian provincial securities regulatory authorities for a more detailed discussion of some of the factors underlying forward-looking statements, and the risks that may affect Barrick’s ability to achieve the expectations set forth in the forward-looking statements contained in this press release.
Barrick disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.